tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

SUPN Stock Latest News

Supernus Pharmaceuticals Reports Strong Q3 2024 Results
Company AnnouncementsSupernus Pharmaceuticals Reports Strong Q3 2024 Results
2M ago
SUPN
Supernus reports Q3 EPS 69c, consensus 44c
PremiumThe Fly
Supernus reports Q3 EPS 69c, consensus 44c
2M ago
SUPN
Supernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
PremiumThe Fly
Supernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
2M ago
SUPN
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
PremiumThe Fly
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
2M ago
SUPN
Is SUPN a Buy, Before Earnings?
PremiumPre-Earnings
Is SUPN a Buy, Before Earnings?
2M ago
SUPN
Supernus announces data from SPN-820 study
PremiumThe FlySupernus announces data from SPN-820 study
2M ago
SUPN
Supernus announces data from SPN-820 study
Premium
The Fly
Supernus announces data from SPN-820 study
2M ago
SUPN
Supernus announces ongoing collaboration with Busy Philipps
Premium
The Fly
Supernus announces ongoing collaboration with Busy Philipps
3M ago
SUPN
Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls
3M ago
AR
MS
Piper downgrades Supernus to Neutral on slower Qelbree growth
PremiumThe Fly
Piper downgrades Supernus to Neutral on slower Qelbree growth
3M ago
SUPN
Supernus downgraded to Neutral from Overweight at Piper Sandler
PremiumThe Fly
Supernus downgraded to Neutral from Overweight at Piper Sandler
3M ago
SUPN
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
PremiumThe Fly
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
4M ago
SUPN
Supernus raises 2024 sales outlook to $600M-$625M from $580M-$620M
PremiumThe FlySupernus raises 2024 sales outlook to $600M-$625M from $580M-$620M
5M ago
SUPN
Supernus reports Q2 adjusted operating earnings $45.5M vs. $10M last year
Premium
The Fly
Supernus reports Q2 adjusted operating earnings $45.5M vs. $10M last year
5M ago
SUPN
SUPN Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SUPN Earnings this Week: How Will it Perform?
5M ago
SUPN
Supernus resubmits SPN-830 NDA after addressing complete response letter
PremiumThe Fly
Supernus resubmits SPN-830 NDA after addressing complete response letter
5M ago
SUPN
Supernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
PremiumThe Fly
Supernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
7M ago
SUPN
Supernus sees FY24 revenue $580M-$620M, consensus $601.46M
PremiumThe Fly
Supernus sees FY24 revenue $580M-$620M, consensus $601.46M
8M ago
SUPN
Supernus reports Q1 EPS 0c, consensus 38c
PremiumThe Fly
Supernus reports Q1 EPS 0c, consensus 38c
8M ago
SUPN
M8 Pharmaceuticals signs licensing agreement with Supernus
PremiumThe FlyM8 Pharmaceuticals signs licensing agreement with Supernus
8M ago
SUPN
SUPN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SUPN Upcoming Earnings Report: What to Expect?
8M ago
SUPN
Supernus partners with Busy Philipps to shine spotlight on ADHD in women
Premium
The Fly
Supernus partners with Busy Philipps to shine spotlight on ADHD in women
8M ago
SUPN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >